Global phase 1/2 clinical trial initiated for GBP511, a vaccine targeting the Sarbecovirus Family Next-generation vaccine ...
Recombinant protein vaccines, which are obtained by conventional genetic engineering, are based on the proteins of target pathogens that can activate our immune systems. Unlike other types of vaccines ...
Baculovirus expression systems have emerged as an indispensable tool in the production of recombinant proteins, offering a robust platform for achieving high-level expression in insect cells. By ...
The host cell system is a critical determinant of recombinant protein quality and yield, with direct influence on protein folding and post-translational modification factors that shape the ...
Cytiva introduced a new technology called Protein Select that the company says is designed to streamline and accelerate recombinant protein purification. The self-cleaving traceless tag and ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--NanoTemper Technologies, well known for creating biophysical tools that accelerate the work of drug discovery researchers, brings their groundbreaking ...
According to MarketsandMarkets™, the Proteins & Protein Crystals Market is projected to grow from about USD 609.51 billion in ...
Recombinant antibody technology has been leveraged to mitigate a range of common problems associated with hybridoma platforms, helping to facilitate the development of an entirely new class of ...
The development of early monoclonal antibody (mAb) therapies centered around the hybridoma platform requires the production of target antigen or immunogen and animal immunizations. This means there ...
Epigenome editing has followed a similar path, in that more recent technological breakthroughs have enabled scientists to apply the discoveries made in previous decades. Epigenome editing performs a ...
Perfect Day. has filed a patent for a recombinant protein and compositions. The protein has a specific structure involving milk proteins and linker peptides linked via peptide bonds, with at least one ...